In addition to NSCLC, depleted levels of RAC1, CDC42, and RHOA were also observed in several other cell lines, including lung cancer (A549 and NCI-H1299) and breast cancer (MDA-MB-468 and MDA-MB-231) [46], following PCAIs treatment. This evidence concerns the gene RAC1 and lung cancer.